- Home
- QH vs CRBU Comparison
QH vs CRBU Comparison
Compare QH & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QH | CRBU |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 203.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QH | CRBU |
|---|---|---|
| Price | $1.52 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 784.6K | ★ 999.3K |
| Earning Date | 09-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $357,118,848.00 | $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.66 |
| 52 Week High | $169.07 | $3.54 |
Technical Indicators
Market Signals| Indicator | QH | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 40.56 |
| Support Level | $1.09 | $1.82 |
| Resistance Level | $1.54 | $1.91 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 48.93 | 28.90 |
Price Performance
Historical ComparisonAbout QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.